216 related articles for article (PubMed ID: 12607601)
1. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
Sun W; Zhang PL; Herrera GA
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
Sun W; Herrera GA
Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of atypical papillary urothelial hyperplasia.
Swierczynski SL; Epstein JI
Hum Pathol; 2002 May; 33(5):512-7. PubMed ID: 12094376
[TBL] [Abstract][Full Text] [Related]
4. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
Offner FA; Schäfer G; Hittmair A; Ofner D; Grünewald K; Weyrer K; Mattern D; Eberle J; Mikuz G; Feichtinger H
Verh Dtsch Ges Pathol; 1993; 77():241-6. PubMed ID: 7511289
[TBL] [Abstract][Full Text] [Related]
5. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa.
Palmeira C; Lameiras C; Amaro T; Lima L; Koch A; Lopes C; Oliveira PA; Santos L
Urol Oncol; 2011; 29(2):205-11. PubMed ID: 19854077
[TBL] [Abstract][Full Text] [Related]
6. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia.
Cina SJ; Lancaster-Weiss KJ; Lecksell K; Epstein JI
Arch Pathol Lab Med; 2001 May; 125(5):646-51. PubMed ID: 11300936
[TBL] [Abstract][Full Text] [Related]
8. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
10. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
Mallofré C; Castillo M; Morente V; Solé M
Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
14. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer.
Moch H; Sauter G; Mihatsch MJ; Gudat F; Epper R; Waldman FM
Hum Pathol; 1994 Dec; 25(12):1346-51. PubMed ID: 8001930
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells.
Kuncová J; Urban M; Mandys V
APMIS; 2007 Nov; 115(11):1194-205. PubMed ID: 18092951
[TBL] [Abstract][Full Text] [Related]
17. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder.
Kilicli-Camur N; Kilicaslan I; Gulluoglu MG; Esen T; Uysal V
Pathol Int; 2002 Jul; 52(7):463-9. PubMed ID: 12167105
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder.
Popov Z; Hoznek A; Colombel M; Bastuji-Garin S; Lefrere-Belda MA; Bellot J; Abboh CC; Mazerolles C; Chopin DK
Cancer; 1997 Oct; 80(8):1472-81. PubMed ID: 9338472
[TBL] [Abstract][Full Text] [Related]
19. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
[TBL] [Abstract][Full Text] [Related]
20. P53 accumulation in precursor lesions and early stages of bladder cancer.
Schmitz-Dräger BJ; van Roeyen CR; Grimm MO; Gerharz CD; Decken K; Schulz WA; Bültel H; Makri D; Ebert T; Ackermann R
World J Urol; 1994; 12(2):79-83. PubMed ID: 8087143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
